Protection from Ebola Virus Mediated by Cytotoxic T Lymphocytes Specific for the Viral Nucleoprotein
- 15 March 2001
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 75 (6), 2660-2664
- https://doi.org/10.1128/jvi.75.6.2660-2664.2001
Abstract
Cytotoxic T lymphocytes (CTLs) are proposed to be critical for protection from intracellular pathogens such as Ebola virus. However, there have been no demonstrations that protection against Ebola virus is mediated by Ebola virus-specific CTLs. Here, we report that C57BL/6 mice vaccinated with Venezuelan equine encephalitis virus replicons encoding the Ebola virus nucleoprotein (NP) survived lethal challenge with Ebola virus. Vaccination induced both antibodies to the NP and a major histocompatibility complex class I-restricted CTL response to an 11-amino-acid sequence in the amino-terminal portion of the Ebola virus NP. Passive transfer of polyclonal NP-specific antiserum did not protect recipient mice. In contrast, adoptive transfer of CTLs specific for the Ebola virus NP protected unvaccinated mice from lethal Ebola virus challenge. The protective CTLs were CD8+, restricted to the Dbclass I molecule, and recognized an epitope within amino acids 43 to 53 (VYQVNNLEEIC) in the Ebola virus NP. The demonstration that CTLs can prevent lethal Ebola virus infection affects vaccine development in that protective cellular immune responses may be required for optimal protection from Ebola virus.Keywords
This publication has 18 references indexed in Scilit:
- Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virusVaccine, 2000
- Human asymptomatic Ebola infection and strong inflammatory responseThe Lancet, 2000
- Epitopes Involved in Antibody-Mediated Protection from Ebola VirusScience, 2000
- Quantitative aspects of T cell activation—peptide generation and editing by MHC class I moleculesSeminars in Immunology, 1999
- The Reemergence of Ebola Hemorrhagic Fever, Democratic Republic of the Congo, 1995The Journal of Infectious Diseases, 1999
- Evaluation of Immune Globulin and Recombinant Interferon‐α2b for Treatment of Experimental Ebola Virus InfectionsThe Journal of Infectious Diseases, 1999
- Preparation and Use of Hyperimmune Serum for Prophylaxis and Therapy of Ebola Virus InfectionsThe Journal of Infectious Diseases, 1999
- DNA Vaccines Expressing either the GP or NP Genes of Ebola Virus Protect Mice from Lethal ChallengeVirology, 1998
- Replicon-Helper Systems from Attenuated Venezuelan Equine Encephalitis Virus: Expression of Heterologous Genesin Vitroand Immunization against Heterologous Pathogensin VivoVirology, 1997
- Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides.Proceedings of the National Academy of Sciences of the United States of America, 1991